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Objective Type 2 diabetic patients have an increased
arterial stiffness and a very high risk of cardiovascular
death. The present study investigated the relationship
between pulse pressure, an indicator of vascular stiffness,
and risk of cardiovascular mortality among type 2 diabetic
and non-diabetic individuals. Second, we determined the
relationship between pulse pressure and its main
determinant (i.e. age), and the influence of diabetes and
mean arterial pressure on this relationship.
Design and methods We studied a cohort of 2484
individuals including 208 type 2 diabetic patients. Mean
age and median follow-up for non-diabetic and diabetic
individuals, respectively, were 61 and 66 years, and 8.8 and
8.6 years. One-hundred and sixteen non-diabetic and 34
diabetic individuals died of cardiovascular causes. Relative
risks of cardiovascular mortality were estimated by Cox
proportional hazards regression adjusted for age, gender
and mean arterial pressure.
Results Pulse pressure was associated with
cardiovascular mortality among the diabetic, but not
among the non-diabetic individuals [adjusted relative risk
(95% confidence interval) per 10 mmHg increase, 1.27
(1.00–1.61) and 0.98 (0.85–1.13), P interaction 0.07].
Further adjustment for other risk factors gave similar
results. The association, at baseline, between age and
pulse pressure was dependent on the presence of
diabetes (P interaction 0.03) and on the mean arterial
pressure (P interaction < 0.001) (i.e. there was a stronger
association when diabetes was present and when mean
arterial pressure was higher).
Conclusions We conclude that, in type 2 diabetes, pulse
pressure is positively associated with cardiovascular
mortality. The association between age and pulse pressure
is influenced by the presence of type 2 diabetes and by the
height of the mean arterial pressure. These findings
support the concept of accelerated vascular aging in type 2
diabetes. J Hypertens 20:1743–1751 & 2002 Lippincott
Williams & Wilkins.
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Introduction
Vascular stiffness is associated with cardiovascular dis-
ease and mortality [1–10]. Vascular stiffness increases
myocardial afterload and oxygen demand, leads to left
ventricular hypertrophy, and limits coronary filling dur-
ing diastole [11]. Over 50 years of age, pulse pressure is
regarded as a manifestation of arterial stiffness, and
several studies have shown a relationship between
pulse pressure and cardiovascular mortality [6,12–16].
Type 2 diabetic patients are at very high risk of
cardiovascular death [17–22] and are thought to have
an increased arterial stiffness [23] and increased pulse
pressure [15,24–26]. However, it is not known whether
pulse pressure is positively associated with cardio-
vascular mortality in these patients, nor whether any
such relationship is similar in diabetic and non-diabetic
individuals. In addition, it is not known whether the
increase of pulse pressure in diabetes is related to the
accelerated vascular aging that is thought to occur
in diabetes [27], in which case one would expect a
stronger association between age and pulse pressure
than in non-diabetic individuals.
Therefore, we investigated these issues among type 2
diabetic and non-diabetic individuals in a prospective,
population-based cohort study.
Subjects and methods
The Hoorn Study is a population-based cohort study on
glucose intolerance in a Dutch population conducted
from 1989 until 1992. We invited a random sample of
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3553 50- to 74-year-old individuals taken from the
population register of the town of Hoorn, The Nether-
lands; 2484 participated (response rate, 71%). The
study cohort and baseline measurement have been
described in detail previously [28]. All subjects, except
previously diagnosed diabetic individuals treated with
oral glucose-lowering agents or insulin, underwent an
oral glucose tolerance test according to the guidelines
of the World Health Organization [29]. On the basis of
this test, glucose tolerance was divided into two cate-
gories: normal and impaired glucose tolerance
(n ¼ 2260), and type 2 diabetes (n ¼ 208). In 16 sub-
jects, no data on glucose tolerance were available.
Blood pressure was measured twice on the right arm of
seated subjects, after at least 5 min of rest, with a
random-zero sphygmomanometer (Hawksley-Gelman
Ltd, Lancing, Sussex, UK). Hypertension was defined
as diastolic blood pressure > 95 mmHg, systolic blood
pressure > 160 mmHg and/or treatment with anti-
hypertensive drugs, in accordance with clinical practice
at the time the baseline data for this study were
collected. Mean arterial pressure was defined as two-
thirds of diastolic blood pressure plus one-third of
systolic blood pressure. Pulse pressure was defined as
systolic blood pressure minus diastolic blood pressure.
The average of duplicate measurements was used for
analysis. Body mass index, waist-to-hip ratio, specific
fasting insulin, total cholesterol, high-density lipo-
protein cholesterol (HDL), low-density lipoprotein
cholesterol (LDL), triglycerides, smoking habits, and
prior cardiovascular disease were determined as
previously described [28].
Follow-up
Data on the vital status of the subjects on 1 January
2000 were collected from the mortality register of the
municipality of Hoorn as previously described [30]. For
all subjects who died, the cause of death was extracted
from the medical records of the general practitioner
and the hospital of Hoorn, and classified according to
the ninth edition of the International Classification of
Diseases (ICD-9) [31]. Cardiovascular mortality was
defined as codes 390–459, (‘Diseases of the circulatory
system’) or code 798 (‘Sudden death, cause unknown’),
because sudden death in general is of cardiovascular
origin [30]. Seventeen subjects (0.7% of the study
cohort) were lost to follow-up. All participants gave
informed consent for this study, which was approved by
the Ethics Committee of the Vrije Universiteit Medical
Centre, Amsterdam.
Statistical analysis
All analyses were performed with SPSS 9.0 for Win-
dows 95 (SPSS Inc., Chicago, Illinois, USA). The
associations between pulse pressure and cardiovascular
risk factors were investigated by multiple linear regres-
sion analyses, with pulse pressure as the dependent
variable and risk factors as independent variables.
Survival over the follow-up period was calculated by
Kaplan–Meier curves for different groups. Differences
were tested by the log-rank test for trend. Cox propor-
tional hazards multiple regression analysis was per-
formed to assess the associations of pulse pressure and
risk factors with cardiovascular and all-cause mortality.
Results are described as relative risks (RR) (hazard
ratios) with 95% confidence intervals (95% CI). The
analyses were adjusted for all variables that were
significantly associated with cardiovascular mortality,
that were significantly associated with pulse pressure,
or that were of pathophysiological interest. To evaluate
possible interaction between pulse pressure and risk
factors of interest, their product term, and age, gender
and mean arterial pressure were added to the model.
Risk factors measured on a continuous scale were used
as such in the regression model, except for levels of
fasting specific insulin, body mass index, HDL choles-
terol, and triglycerides because the association of these
variables with mortality was non-linear (see footnote to
Table 1 for cut-off points).
Pulse pressure was entered into the regression model
as a continuous variable, since the association with
all-cause and cardiovascular mortality appeared to
be linear. The proportional hazards assumption was
checked by use of a hazard function plot. To examine
the relationship of pulse, systolic, diastolic and mean
arterial pressure with age, multiple linear regression
was used with adjustment for gender and the presence
of type 2 diabetes. Possible interactions between age
and diabetes or age and mean arterial pressure in the
associations of age with the measures of blood pressure
were assessed with interaction terms in multiple regres-
sion. P , 0.05 was considered statistically significant.
Results
Clinical characteristics
Table 1 shows the baseline characteristics of the study
population and RR (95% CI) of mortality associated
with risk factors after adjustment for age and gender
(columns on the right). Median duration of follow-up
was 8.6 years (range, 0.5–10.2 years) for diabetic and
8.8 years (range, 0.2–10.2 years) for non-diabetic indivi-
duals. During follow-up, 65 of 208 diabetic individuals
died [34 of cardiovascular disease, five of whom died of
cerebrovascular disease (ICD-9 codes 431–436)] com-
pared with 265 of 2260 non-diabetic individuals (116 of
cardiovascular disease, 16 of whom died of cerebro-
vascular disease). Of three patients who died, all of
non-cardiovascular causes, glucose tolerance data were
missing. Fifty-five diabetic individuals had prior cardio-
vascular disease (acute myocardial infarction in 17,
angina pectoris in 21, coronary bypass or angioplasty in
11, intermittent claudication in 10, cerebrovascular
disease in 14 and nitrate treatment in 15). Three
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Table 1 Baseline characteristics and relative risk of cardiovascular and all-cause mortality with risk factors
Cardiovascular mortality [RR (95% CI)]a All-cause mortality [RR (95% CI)]a
Risk factor
Diabetic
individuals
(n ¼ 208)
Non-diabetic
individuals
(n ¼ 2260)
Difference in
risk factor or
indicator
Diabetic
individuals
(34 cases)
Non-diabetic
individuals
(116 cases)
Diabetic
individuals
(65 cases)
Non-diabetic
individuals
(265 cases)
Male gender (%) 43 46 Yes vs. no 0.95 (0.47–1.95)b 2.77 (1.87–4.09)b 1.61 (0.98–2.65)b 2.05 (1.59–2.62)b
Age (years) 65.6  6.8 61.3  7.3 Per 5-year increase 1.68 (1.24–2.28)b 1.75 (1.53–2.00)b 1.75 (1.41–2.19)b 1.63 (1.49–1.77)b
Fasting insulin (pmol/l) 108 (75–143) 76 (60–97) High vs. lowc 0.82 (0.40–1.69) 1.45 (1.00–2.09) 1.01 (0.60–1.71) 1.15 (0.89–1.48)
Waist-to-hip ratio 0.95  0.08 0.89  0.09 Per 0.1 increase 1.09 (0.67–1.79) 1.50 (1.14–1.98) 1.38 (0.97–1.98) 1.38 (1.14–1.66)
Body mass index (kg/m2) 28.6  4.5 26.3  3.4 High vs. lowd 1.37 (0.62–3.02) 1.17 (0.80–1.72) 1.11 (0.65–1.90) 1.12 (0.87–1.44)
Total cholesterol (mmol/l) 6.6  1.3 6.7  1.2 Per 1.0 mmol/l increase 1.20 (0.95–1.51) 1.20 (1.03–1.40) 1.11 (0.93–1.33) 1.08 (0.97–1.20)
High-density lipoprotein cholesterol (mmol/l) 1.2  0.3 1.3  0.4 Low vs. highe 1.57 (0.66–3.75) 2.02 (1.22–3.36) 1.06 (0.55–2.03) 1.70 (1.19–2.45)
Low-density lipoprotein cholesterol (mmol/l) 4.4  1.2 4.6  1.1 Per 1.0 mmol/l increase 1.17 (0.90–1.53) 1.25 (1.06–1.46) 1.06 (0.87–1.29) 1.07 (0.95–1.19)
Triglycerides (mmol/l) 1.9 (1.3–2.8) 1.3 (1.0–1.8) High vs. lowf 2.21 (1.10–4.44) 1.40 (0.93–2.11) 2.23 (1.34–3.71) 1.15 (0.87–1.53)
Current smokers (%) 25.0 32.1 Yes vs. no 1.27 (0.57–2.84) 2.08 (1.42–3.03) 1.35 (0.77–2.37) 1.73 (1.34–2.23)
Prior cardiovascular disease (%) 26.4 14.8 Yes vs. nog 1.92 (0.97–3.83) 3.08 (2.11–4.48) 1.38 (0.83–2.31) 2.12 (1.63–2.76)
Hypertension (%) 60.6 29.1 Yes vs. no 3.44 (1.32–8.98) 2.62 (1.81–3.81) 1.37 (0.80–2.34) 1.95 (1.53–2.50)
Use of anti-hypertensive drugs (%) 40.9 18.2 Yes vs. no 2.29 (1.11–4.71) 2.58 (1.77–3.77) 1.27 (0.77–2.10) 1.91 (1.47–2.48)
Pulse pressure (mmHg) 62  17 52  15 Per 10 mmHg 1.27 (1.04–1.55) 1.08 (0.96–1.22) 1.13 (0.97–1.32) 1.08 (0.99–1.17)
Systolic blood pressure (mmHg) 146  20 134  20 Per 10 mmHg 1.18 (1.00–1.40) 1.11 (1.01–1.21) 1.09 (0.96–1.24) 1.08 (1.02–1.15)
Diastolic blood pressure (mmHg) 84  10 82  10 Per 10 mmHg 1.05 (0.74–1.47) 1.23 (1.05–1.45) 1.05 (0.82–1.33) 1.14 (1.02–1.27)
Mean arterial pressure (mmHg) 104  12 99  12 Per 10 mmHg 1.20 (0.90–1.60) 1.20 (1.05–1.38) 1.11 (0.90–1.36) 1.13 (1.03–1.24)
aRelative Risk (RR) with 95% confidence intervals (95% CI) obtained with Cox regression analyses of cardiovascular and all-cause mortality associated with continuous or dichotomous variables after adjustment for age and
gender. bThe effects of age and gender were only adjusted for each other. c. 90 pmol/l versus < 90 pmol/l. d. 27 kg/m2 versus < 27 kg/m2 for males and . 26kg/m2 versus < 26 kg/m2 for females. e. 0.9 mmol/l versus
> 0.9 mmol/l. f. 2.0 mmol/l versus < 2.0 mmol/l. gA history of cardiovascular disease according to the Rose questionnaire [48].
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hundred and thirty-four non-diabetic individuals had
prior cardiovascular disease (acute myocardial infarction
in 117, angina pectoris in 112, coronary bypass or
angioplasty in 68, intermittent claudication in 15,
cerebrovascular disease in 94, and nitrate treatment in
77).
Mortality and pulse pressure
The mean  SD pulse pressure at baseline in the
subjects who died was higher than in those who
survived (60  17 versus 52  15 mmHg, P ¼ 0.003).
Figure 1 shows the percentage of subjects with a pulse
pressure above 62 mmHg (the upper quartile of the
distribution) in type 2 diabetic and non-diabetic indivi-
duals. Figure 2 shows cardiovascular survival according
to quartiles of pulse pressure. Table 2 presents the RR
of cardiovascular and all-cause mortality associated with
a 10 mmHg increase of pulse pressure.
Among diabetic individuals, pulse pressure was posi-
tively associated with cardiovascular mortality (crude
RR, 1.40; 95% CI, 1.16–1.68). After adjustment for age,
gender and mean arterial pressure, the RR was 1.27
(95% CI, 1.00–1.61). The crude and adjusted RR for
the association of pulse pressure with all-cause mortal-
ity were 1.26 (95% CI, 1.09–1.45) and 1.12 (95% CI,
0.93–1.34). Adjustment for systolic blood pressure
instead of mean arterial pressure did not materially
change the RR (Table 2).
Among non-diabetic individuals, pulse pressure was
significantly associated with cardiovascular and all-cause
mortality in crude analyses. However, these associations
were confounded by age and, to a lesser extent, by
mean arterial pressure and gender [adjusted RR, 0.98
(95% CI, 0.85–1.13) and 1.02 (95% CI, 0.92–1.12)].
The associations of cardiovascular and all-cause mortal-
ity with pulse pressure were somewhat, but not sig-
nificantly, stronger than those with systolic blood
pressure in both diabetic and non-diabetic individuals
(data not shown).
The associations between pulse pressure and mortality
were not importantly affected by further adjustment for
prior cardiovascular disease, current smoking, HDL
cholesterol, LDL cholesterol and total cholesterol,
triglycerides, waist-to-hip ratio, body mass index, and
the use of antihypertensive drugs (Table 2).
Exclusion of individuals with prior cardiovascular dis-
ease did not materially change the results (data not
shown).
We considered that the association between pulse
pressure and mortality might be confounded by im-
paired renal function. Data on serum creatinine and
urinary albumin excretion were available in a subgroup
[32], which included all diabetic individuals. Analyses
adjusted for Cockroft–Gault-estimated glomerular fil-
tration [33] (n ¼ 631) were similar to those without such
adjustment (data not shown). Analyses adjusted for the
presence of microalbuminuria and macroalbuminuria
among those in whom such data were available (n ¼
575) did not materially change the association between
pulse pressure and cardiovascular mortality (data not
shown), but decreased the association of pulse pressure
with all-cause mortality among diabetic individuals
Non-diabetic individuals Diabetic individuals
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Fig. 1
Percentage of individuals with pulse pressure in the upper quartile
(. 62 mmHg) of the entire cohort, according to the presence of
diabetes.
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Fig. 2
Cardiovascular survival (Kaplan–Meier curves) according to pulse
pressure (PP) in the lowest (, 42 mmHg), second (42–50 mmHg),
third (51–61 mmHg) and highest (> 62 mmHg) quartile of the entire
cohort.
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(RR, 1.00), but the confidence interval was wide (95%
CI, 0.79–1.27).
The association between pulse pressure and cardio-
vascular mortality differed between diabetic and
non-diabetic individuals (P ¼ 0.07 for pulse pressure-
by-diabetes interaction in a model adjusted for age,
gender and mean arterial pressure that included the
whole population).
All analyses presented in Table 2 were also performed
with the exclusion of hypertensive subjects and users
of antihypertensive drugs. The results of these analyses
were similar to the results presented here. Analyses
stratified for gender showed similar RR for men and
women (data not shown). Analyses in individuals with
impaired glucose tolerance (n ¼ 252) indicated that RR
were similar to those in individuals with normal glucose
tolerance (data not shown).
Cross-sectional associations of measures of blood
pressure with age and diabetes at baseline
Pulse pressure among diabetic individuals was 3.2
mmHg (95% CI, 1.6–4.9) higher than among non-
diabetic individuals after adjustment for age, gender
and mean arterial pressure. Age was associated with
pulse pressure both among diabetic and non-diabetic
individuals, but the association was stronger among
diabetic individuals. Pulse pressure increased by 0.98
mmHg per year of age in diabetic and by 0.71 mmHg
per year of age in non-diabetic individuals. This differ-
ence was statistically significant as tested by the inter-
action term of age with the presence of type 2 diabetes
(P interaction ¼ 0.03; Fig. 3). Exclusion of individuals
with impaired glucose tolerance did not change the
results.
Mean arterial pressure is an additional important deter-
minant of pulse pressure. Pulse pressure increased with
6.37 mmHg per 10 mmHg increase in mean arterial
pressure after adjustment for age and gender (Table 3).
The association between pulse pressure and mean
arterial pressure was similar among diabetic and non-
diabetic individuals (7.09 versus 6.27 mmHg, P inter-
action ¼ 0.219).
The association between age and systolic blood pres-
sure also increased more with age in diabetic compared
with non-diabetic individuals. Systolic blood pressure
increased by 0.67 mmHg per year of age in the diabetic
and by 0.48 mmHg per year of age in the non-diabetic
individuals (P interaction ¼ 0.03; Table 4). In addition,
Table 2 Relative risk of cardiovascular and all-cause mortality associated with pulse pressure increase after adjustment for potentially
confounding risk factors
Cardiovascular mortality [RR (95% CI)]a All-cause mortality [RR (95% CI)]a
Model Determinants in the model
Non-diabetic subjects
(116 cases)
Diabetic subjects
(34 cases)
Non-diabetic subjects
(265 cases)
Diabetic subjects
(65 cases)
1 Pulse pressure per 10 mmHg 1.27 (1.14–1.41) 1.40 (1.16–1.68) 1.25 (1.17–1.34) 1.26 (1.09–1.45)
2 Model 1 and age 1.05 (0.93–1.18) 1.27 (1.03–1.55) 1.05 (0.97–1.14) 1.11 (0.95–1.30)
3 Model 2 and gender 1.08 (0.96–1.22) 1.27 (1.04–1.55) 1.08 (0.99–1.17) 1.13 (0.97–1.32)
4 Model 3 and mean arterial pressure 0.98 (0.85–1.13) 1.27 (1.00–1.61) 1.02 (0.92–1.12) 1.12 (0.93–1.34)
5 Model 3 and systolic blood pressure 0.86 (0.69–1.08) 1.26 (0.84–1.90) 0.95 (0.81–1.10) 1.10 (0.81–1.48)
6 Model 4 and prior cardiovascular diseaseb 0.98 (0.85–1.14) 1.25 (0.98–1.59) 1.02 (0.93–1.13) 1.10 (0.91–1.33)
7 Model 4 and current smoking 0.96 (0.83–1.11) 1.26 (1.00–1.63) 1.01 (0.91–1.11) 1.11 (0.92–1.34)
8 Model 4 and high-density lipoprotein cholesterolb 0.98 (0.85–1.14) 1.28 (1.01–1.63) 1.02 (0.93–1.12) 1.12 (0.93–1.35)
9 Model 4 and low-density lipoprotein cholesterol 0.98 (0.85–1.13) 1.30 (1.02–1.66) 1.02 (0.92–1.12) 1.13 (0.94–1.36)
10 Model 4 and total cholesterol 0.98 (0.85–1.13) 1.26 (1.00–1.60) 1.02 (0.92–1.12) 1.12 (0.93–1.34)
11 Model 4 and triglyceridesb 0.98 (0.85–1.14) 1.25 (0.99–1.58) 1.02 (0.93–1.12) 1.11 (0.93–1.33)
12 Model 4 and waist-to-hip ratio 0.98 (0.85–1.14) 1.28 (1.01–1.63) 1.02 (0.92–1.12) 1.13 (0.94–1.35)
13 Model 4 and body mass index 0.97 (0.84–1.13) 1.28 (1.01–1.64) 1.02 (0.92–1.12) 1.13 (0.94–1.36)
14 Model 4 and use of anti-hypertensive drugs 0.97 (0.84–1.12) 1.29 (1.02–1.63) 1.01 (0.92–1.12) 1.12 (0.94–1.35)
aRelative risk (RR) with 95% confidence interval (95% CI) obtained with Cox regression analyses of cardiovascular and all-cause mortality adjusted for several risk
factors. bDefined footnote to Table 1.
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Fig. 3
The association between pulse pressure and age. The association is
stronger in diabetic than in non-diabetic individuals and was tested
statistically by the interaction term of age with the presence of type 2
diabetes (P interaction ¼ 0.03).
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diastolic blood pressure decreased more with age in
diabetic than in non-diabetic individuals. Diastolic
blood pressure decreased by 0.34 mmHg per year of
age in the diabetic and by 0.24 mmHg per year of age
in the non-diabetic individuals (P interaction ¼ 0.03;
Table 4). Mean arterial pressure also decreased more
with age in diabetic compared with non-diabetic sub-
jects (P interaction ¼ 0.03; Table 4).
Age and mean arterial pressure interacted in their
relationship with pulse, systolic and diastolic pressure
(P interaction , 0.001). The complete model for pulse
Table 3 Cross-sectional associations of pulse pressure with cardiovascular risk factorsa
Regression
coefficient Standard error P value
Crude
Mean arterial pressure (per 1 mmHg increase) 0.713 0.021 , 0.001
Adjusted for age and gender
Mean arterial pressure (per 1 mmHg increase) 0.637 0.019 , 0.001
Gender (male versus female) 1.862 0.557 0.001
Age (per 5 year increase) 4.834 0.188 , 0.001
Adjusted for age, gender and mean arterial pressure
Gender (male versus female) 3.219 0.463 , 0.001
Age (per 5 year increase) 3.778 0.159 , 0.001
Diabetes mellitus type 2 (yes versus no) 3.238 0.838 , 0.001
Fasting insulin (high versus low)b 1.139 0.503 0.024
Hypertension (yes versus no) 2.000 0.596 0.001
Current smoking (yes versus no) 2.028 0.504 , 0.001
aRegression coefficient, standard error and P value obtained by linear regression analyses with pulse
pressure as dependent and risk factors as independent variable. bDefined in footnote to Table 1. A
regression coefficient of 0.713 (top left) indicates that, for each 1 mmHg increase in mean arterial pressure,
pulse pressure increases by 0.713 mmHg.
Table 4. Cross-sectional associations of systolic, diastolic and mean arterial pressure with
age
Regression
coefficient Standard error P-value
Systolic blood pressure
Crude
Age (per 5 year increase) 0.502 0.027 ,0.0001
Adjusted for age, gender, mean arterial pressure, diabetes and interactions
Age (per 5 year increase) 0.563 0.838 0.502
Mean arterial pressure (per 1 mmHg) 1.053 0.105 ,0.0001
Diabetes mellitus type 2 (yes vs no) 9.308 5.322 0.080
Age 3 diabetes 0.879 0.405 0.030
Age 3 mean arterial pressure 0.030 0.008 ,0.001
Diastolic blood pressure
Crude
Age (per 5 year increase) 0.000 0.015 0.991
Adjusted for age, gender, mean arterial pressure, diabetes and interactions
Age (per 5 year increase) 0.282 0.419 0.502
Mean arterial pressure (per 1 mmHg) 0.973 0.052 ,0.0001
Diabetes mellitus type 2 (yes versus no) 4.654 2.661 0.080
Age 3 diabetes 0.439 0.203 0.030
Age 3 mean arterial pressure 0.015 0.004 ,0.001
Mean arterial pressure
Crude
Age (per 5 year increase) 1.672 0.175 ,0.0001
Adjusted for age, gender, diabetes and age 3 diabetes
Age (per 5 year increase) 1.620 0.175 ,0.0001
Diabetes mellitus type 2 (yes versus no) 22.410 8.508 0.008
Age 3 diabetes 1.434 0.648 0.027
Regression coefficient, standard error and P-value obtained by linear regression analyses with systolic,
diastolic or mean arterial pressure as dependent variables. A regression coefficient of 0.502 (top left)
indicates that, for each 5 year increase in age, systolic pressure increases by 0.502 mmHg. Note that the full
effect of age, mean arterial pressure and diabetes can be calculated in a manner analogous to that shown in
the text for pulse pressure.
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pressure, including the interactions of age with diabetes
and age with mean arterial pressure (MAP), was:
pulse pressure ¼ 2:023 0:169 ageþ 0:080 MAP
þ 0:009 age3MAP
 13:962 diabetesþ 0:264 diabetes
3 age 3:067 gender:
The interaction of age with mean arterial pressure
means that the association between, in this case, pulse
pressure and age is stronger at a higher mean arterial
pressure (Fig. 4). Thus, for non-diabetic women with a
mean arterial pressure of 90 mmHg, pulse pressure
increased by 0.64 mmHg per year, while for non-
diabetic women with a mean arterial pressure of
110 mmHg, the increase was 0.82 mmHg per year. The
interaction between age and mean arterial pressure
with regard to pulse pressure was similar among
diabetic and non-diabetic individuals.
Discussion
The present study demonstrates, to our knowledge for
the first time, that pulse pressure is independently
associated with cardiovascular mortality in individuals
with type 2 diabetes. These patients have a 27%
increased risk of cardiovascular death per 10 mmHg
increase of pulse pressure. In addition, we show that
the pulse pressure increase typically observed in type 2
diabetes is, in part, related to a stronger association of
pulse pressure with age compared with non-diabetic
individuals. This finding supports the concept that type
2 diabetes can be regarded as a state of accelerated
vascular aging.
Among non-diabetic individuals, pulse pressure was
significantly associated with cardiovascular mortality in
crude analysis. After adjustment for age, gender and
mean arterial pressure, the relationship disappeared.
These findings differ from those reported by others
[12,13,16,34]. The explanation for this discrepancy is
unclear and may be multifactorial. First, many studies
did not adjust the association between pulse pressure
and mortality for the influence of mean arterial pressure
[12,13,16,34], which is an important confounder of this
association (Table 2). Failure to adjust for mean arterial
pressure leads to higher estimated levels of RR, and
thus to an overestimation of the influence of pulse
pressure on mortality risk. Second, our study had a
relatively short follow-up and very low mortality rate
compared with other population-based studies, whereas
studies with a longer follow-up and higher mortality
rates generally report stronger associations between
pulse pressure and mortality (7.2 per 1000 person-years
for cardiovascular mortality in our study, compared with
1.7–48.6 per 1000 person-years in other studies) [12–
16]. The association between pulse pressure and cardio-
vascular mortality may thus be more prominent among
populations with higher mortality risk than our popu-
lation. In this regard, it should be noted that we cannot
exclude that our findings among the diabetic indivi-
duals were related to their high-risk status rather than
to the diabetic state per se.
Vascular aging encloses a broad spectrum of changes in
the arterial vessel wall, including increased stiffening.
Our data support the concept of accelerated vascular
aging in diabetic individuals. First, we found that,
among diabetic individuals, both the age-related in-
crease of systolic blood pressure and the age-related
decrease of diastolic blood pressure were more pro-
nounced than among non-diabetic individuals (Table 4)
[3,35–37]. Therefore, it is likely that the increase in
pulse pressure among diabetic individuals reflects in-
creased arterial stiffness rather than alterations in
ventricular ejection. Second, accelerated vascular aging
in diabetes is biologically plausible. During aging,
collagen in large arteries becomes more prominent,
while elastin fibers become disrupted, leading to stiffer
vessel walls. In diabetes, increases in oxidative stress,
carbonyl stress and advanced glycation endproducts
may combine to exaggerate these alterations in collagen
and elastin structure and function, with resultant loss of
vascular elasticity [27,35,36].
The rise of pulse pressure with age was, in addition,
stronger at higher mean arterial pressure (Fig. 4) [37–
39]. The Framingham study [38] reported an inter-
action between age and hypertension in the association
with pulse pressure, which is comparable with the
interaction between mean arterial pressure and age we
report, because mean arterial pressure is an indicator of
hypertension. One interpretation of the interaction of
age with mean arterial pressure is that it, too, may
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The association between pulse pressure and age. The association is
stronger at higher mean arterial pressure (MAP) and was tested
statistically by the interaction term of age with MAP (P interaction ,
0.001).
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represent accelerated arterial aging at higher mean
arterial pressure. Static wall stress increases with mean
arterial pressure, which will cause tissue fatigue char-
acterized by alterations in collagen and elastin, and
increased arterial stiffness [37,40].
The elevated pulse pressure observed in the type 2
diabetic patients, and the associated elevation in cardio-
vascular risk, may imply that pulse pressure, in addition
to mean arterial pressure, is a target for therapeutic
intervention in these patients. However, it is not clear
how pulse pressure or arterial stiffness can be reduced.
Current antihypertensive treatments often focus on
reduction of the extracellular volume or smooth muscle
cell tone, thereby reducing both systolic and diastolic
blood pressure. When both pressures are reduced, pulse
pressure may not have changed. Some non-pharmaco-
logical efforts may be able to reduce arterial stiffness;
for instance, physical exercise [41,42], reduction of salt
intake [43] and the intake of n-3 fatty acids [44].
Furthermore, some evidence exists that angiotensin-
converting enzyme inhibitors may have a direct effect
on large artery wall properties, thereby reducing arterial
stiffness [45]. They particularly reduce stiffness in
combination with small doses of diuretics [46]. Novel
therapeutic drugs, such as ALT-711 [47], which breaks
down established advanced glycation endproduct cross-
links between proteins, have been demonstrated to
reduce arterial stiffness, but more evidence is necessary
to establish the impact of such drugs.
The present study had several limitations. First, there
were only 34 cardiovascular deaths among the diabetic
individuals, which limits the precision of the risk
estimates. However, we tested a pre-specified hypo-
thesis and the results are biologically plausible. Second,
we were not able to show a difference in the association
between pulse pressure and cardiovascular mortality in
the subgroup of impaired glucose tolerance compared
with the group with normal glucose tolerance, which
may be due to the small number of deaths in this
subgroup (n ¼ 20). Both limitations may be related to
the relatively short follow-up period and the apparently
healthy state of our population.
In summary, our data provide the first evidence that
pulse pressure is independently associated with cardio-
vascular mortality in type 2 diabetic individuals.
Furthermore, the presence of diabetes and a high mean
arterial pressure increase the (normal) rise of pulse
pressure with age. This may represent accelerated
vascular aging in diabetes and hypertension.
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